Currently, Adma Biologics Inc [ADMA] is trading at $6.39, up 1.59%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ADMA shares have gain 7.58% over the last week, with a monthly amount glided 21.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, March 2024, ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®. In a post published today on Yahoo Finance, FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
This stock has fluctuated between a low of $3.03 and a high of $6.47 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $5.25 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $6.39 at the most recent close of the market. An investor can expect a potential drop of -17.84% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
Trailing Twelve Months sales for Adma Biologics Inc [NASDAQ:ADMA] were 258.21M which represents 47.86% growth. Gross Profit Margin for this corporation currently stands at 0.34% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at -0.11%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.24 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.28 points at the first support level, and at 6.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.50, and for the 2nd resistance point, it is at 6.62.
Adma Biologics Inc [ADMA] reported earnings per share of -$0.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.02/share, meaning a difference of -$0.1 and a surprise factor of -500.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.01 per share as compared to estimates of -$0.01 per share, a difference of $0.02 representing a surprise of 200.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adma Biologics Inc [NASDAQ:ADMA] is 5.16. Also, the Quick Ratio is 1.69, while the Cash Ratio stands at 1.03. Considering the valuation of this stock, the price to sales ratio is 5.65, the price to book ratio is 10.68.
Transactions by insiders
Recent insider trading involved ELMS STEVE, Director, that happened on Mar 19 ’24 when 0.41 million shares were sold. Director, ELMS STEVE completed a deal on Mar 18 ’24 to sell 49887.0 shares. Meanwhile, Director ELMS STEVE sold 0.18 million shares on Mar 15 ’24.
